## Practitioner's Docket No.: MPI2000-433CP1(M) PATENT

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Box Patent Application Assistant Commissioner for Patents Washington, D.C. 20231** 

## NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of Inventor(s): Hong Chen and Immaculada Silos-Santiago

For (title): NT69, A Novel Nucleoside Transporter Family Member and Uses Therefor

## 1. Type of Application

This n	ew appli	cation is for a(n)		
	[ ] [ ] [ ] [ ] [X]	Original (nonprovisional) Design Plant Divisional. Continuation. Continuation-in-part (C-I-P).		
		CERTIFICATION UNDER 37 C.F.I (When using Express Mail, the Express Express Mail certifica	Mail lab	el number is mandatory;
I hereby	certify the	at, on the date shown below, this correspondence	is being:	
[X]	Box Pat	MAILI d with the United States Postal Service in an envent Application, 29 Crystal Drive, Arlington, VA 7 C.F.R. Section 1.8(a)	elope add	ressed to the Assistant Commissioner for Patents,  37 C.F.R. Section 1.10*
[]	with suf	ficient postage as first class mail.	[X]	as "Express Mail Post Office to Address"  Mailing Label No. <u>EL791760507US</u> (mandatory)
Date: _	Decemb	er 17, 2001	Signati	Ryan Severson
*WARN	IING:	Each paper or fee filed by "Express Mail" must thereon prior to mailing 37 C.F.R. Section 1.1.		(type or print name of person certifying)  number of the "Express Mail" mailing label placed

"Since the filing of correspondence under [Section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement

will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(New Application Transmittal--page 1 of 5)

[]

[]

[X]

Formal

Informal

Benefit of Prior U.S. Application(s) (35 U.S.C. Sections 119(e), 120, or 121)
[X] The new application being transmitted claims the benefit of prior U.S. Patent Application Number 09/712,797 filed November 14, 2000.
Maintenance of Copendency of Prior Application
A. [ ] Extension of time in prior application
B. [ ] Conditional Petition for Extension of Time in Prior Application
(complete this item, if previous item not applicable)
[ ] A conditional petition for extension of time is being filed in the pending <b>prior</b> application.
[ ] A copy of the conditional petition filed in the prior application is attached.
Abandonment of Prior Application (if applicable)
[ ] Please abandon the prior application at a time while the prior application is pending, or when the petition for extension of time or to revive in that application is granted, and when this application is granted a filing date, so as to make this application copending with said prior application.
Papers Enclosed
Required for Filing Date under 37 C.F.R. Section 1.53(b) (Regular) or 37 C.F.R. Section 1.153 (Design) Application
91 Pages of Specification, including 87 Pages of Description

The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)." 37 C.F.R. Section 1.84(b).

6.	Additional Papers Enclosed					
	[ ] [ ] [ X]	Information Disclosure Statement (37 C.F.R. Section 1.98) Form PTO-1449 (PTO/SB/08A and 08B) Citations Declaration of Biological Deposit 7 pages of paper copy of Sequence Listing (37 CFR Section 1.821-1.823), Diskette containing computer readable form of Sequence Listing (37 CFR Section 1.821(e) and 1.824) and 1 page of Transmittal Letter for Diskette containing computer readable form of Sequence Listing (37 CFR Section 1.821(f)) Authorization of Attorney(s) to Accept and Follow Instructions from Representative Special Comments Other:				
7.	Declaration or Oath (including power of attorney)					
	[X]	(3 pages) An unexecuted Combined Declaration and Power of Attorney, a copy of which is enclosed.				
	[]	Not Enclosed.				
8.	Assignment					
	[X]	An assignment of the invention to Millennium Pharmaceuticals, Inc. a copy of which				
		[ ] is enclosed. [X] will follow.				
	7.	[ ] [ ] [ ] [ ] [ ] [ ] [ ]  7. Declar [ X ]  [ ]  8. Assign				

### 9. Fee Calculation (37 C.F.R. Section 1.16)

#### A. Regular application [X]

		CLAIM	S AS FILED		
Claims	Numbered Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 C.F.R Section 1.16(a)
					\$740.00
Total Claims (37 C.F.R. Section 1.16 (c))	25	- 20 = 5	х	\$18.00	90.00
Independent Claims (37 C.F.R. Section 1.16(b))	10	- 3 = 7	х	\$588.00	588
Multiple Dependent Claim(s), if any (37 C.F.R. Section 1.16(d))	0	+ 280.00			0

Amendment deleting multiple-dependencies is enclosed. []

Fee for extra claims is not being paid at this time. []

ļ =

· · 12

įŁ

Filing Fee Calculation

\$1,418.00

10.	Metho		yment of Fees k in the amount of \$
	[X]		ge Account No. 501668 in the amount of \$1,418.00. plicate of this transmittal is attached.
11.	Autho	The C	a to Charge Additional Fees Commissioner is hereby authorized to charge the following additional fees by this and during the entire pendency of this application to Account No. 501668.
		[X]	37 C.F.R. Section 1.16(a), (f) or (g) (filing fees)
		[X]	37 C.F.R. Section 1.16(b), (c) and (d) (presentation of extra claims)
		[]	37 C.F.R. Section 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)
		[]	37 C.F.R. Section 1.17(a)(1)-(5) (extension fees pursuant to Section 1.136(a).
		[]	37 C.F.R. Section 1.17 (application processing fees)
		[]	37 C.F.R. Section 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. Section 1.311(b))
12.	Instruc [X]		s to Overpayment Account No. 501668.
	[]	Refund	d
			_ Qui E. Uhl
			SIGNATURE OF PRACTITIONER
			Jill E. Uhl, Reg. No. 43,213
			(type or print name of practitioner)
			Millennium Pharmaceuticals, Inc. P.O. Address
			75 Sidney Street
			Cambridge, MA 02139
			Telephone (617) 551-3969
רערו			Facsimile: (617) 551-8820
[X]	C4 1	,	
[]	Statem	ent Wh	ere No Further Pages Added

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Honh Chen et al.

Serial No.: N/A

Filed: Herewith

For: NT69, A Novel Nucleoside Transporter Family

Member and Uses Therefor

Attorney Docket No.: MPI2000-433CP1(M)

Assistant Commissioner for Patents Box Sequence Washington, D.C. 20231

# TRANSMITTAL LETTER FOR DISKETTE CONTAINING COMPUTER READABLE FORM OF SEQUENCE LISTING

Dear Sir:

Enclosed is a diskette which contains a computer readable form of the Sequence Listing for the patent application filed herewith. The Sequence Listing complies with the requirements of 37 C.F.R. § 1.821. The material on this diskette is identical in substance to the Sequence Listing which is submitted herewith, as required by 37 C.F.R. § 1.821(f). The computer readable form of the sequence listing contained on the enclosed diskette is understood to comply with the requirements of § 1.824(d).

Express Mail" mailing label numberEL791760507US
Date of Deposit December 17, 2001
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box Sequence, 2900 Crystal Drive, Arlington, VA 22202
Signature
Ryan Severson
Please Print Name of Person Signing

MILLENNIUM PHARMACEUTICALS, INC.

Registration No.: 43,213 Attorney for Applicant

Millennium Pharmaceuticals, Inc.

75 Sidney Street

Cambridge, MA 02139 Telephone: 617-551-3969 Facsimile: 617-551-8820